Navigation Links
EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study
Date:10/18/2011

BRUSSELS, IRVINE, California, and AMSTERDAM, October 18, 2011 /PRNewswire/ --

The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC 10041/BIG3-04 MINDACT (Microarray In Node negative and 1-3 positive lymph node Disease may Avoid Chemotherapy Trial) study. More than 6,600 patients in 111 institutions across nine countries were enrolled from February 2007 to July 2011 in this trial.

Genomic risk profiling lies at the heart of personalized management of cancer.  MINDACT is investigating the added clinical value of MammaprintTM to standard clinicopathological criteria for the accurate selection of breast cancer patients for adjuvant chemotherapy. The study aims to provide further evidence that early breast cancer patients with a low recurrence risk genomic profile by Mammaprint® may not need chemotherapy.  This would spare patients from burdensome side effects without increasing the risk of metastasis or reducing survival. The study is also designed to show whether MammaPrint® can predict patient response to specific therapies.

Commercialized by Agendia, MammaPrint® has been cleared by the FDA as a prognostic tool identifying patients at low risk of metastasis, and can already be used across the spectrum of breast cancer cases for this purpose (including ER positive and negative, and lymph node negative and positive). It is being tested in MINDACT to provide large-scale prospective validation of its clinical utility.

"The completion of patient recruitment is a major milestone for this groundbreaking trial. If MammaPrint® is ultimately shown to predict individual patient response to the trial specific cancer therapies currently on the market, it will likely create significant and valuable synergies for the manufacturers
'/>"/>

SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Agendia Successfully Completes Bi-Annual FDA Inspection
2. Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
3. Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
4. Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint(R)
5. Agendia Raises US $23 Million in Series E Financing
6. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
7. Agendia Opens CLIA-Registered U.S. Genomics Laboratory
8. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
9. Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference
10. Agendia Presents Data Supporting MammaPrints Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
11. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015   Cypher Genomics, Inc., ... (NASDAQ: SQNM ), the leading molecular ... next generation noninvasive prenatal tests (NIPT). Through this ... called Mantis™, to advance analysis of clinically-relevant fetal ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 ... patient care in critical areas, announced the closing of an ... warrants to purchase up to an aggregate 3,500,000 shares of ... and $.01 per warrant.  The warrants have a per share ...
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... YM BioSciences Inc.,(AMEX: YMI , TSX: YM, ... commercializes differentiated products for patients worldwide,today announced that ... development of the humanized EGFR-targeting monoclonal antibody,nimotuzumab, has ... to commence in Europe. - ...
... 20 The MattsonJack Group, Inc.,(MattsonJack), is pleased ... M.P.H. to Medical Director for MattsonJack. (Photo: ... in September 2000 as a consultant and,Assistant Medical ... the,University of Missouri -- Kansas City. He subsequently ...
... The Chrome Group today announced its,plans to seek ... on trading,platforms in Europe and the Middle East. In ... Officer, Mr. Val Oji said that "this,was part of ... the next two years. Chrome recently signed a Memorandum,of ...
Cached Biology Technology:YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 2YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 3YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 4Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 2Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 3Chrome Group to Seek Listing for Some of its Subsidiaries 2Chrome Group to Seek Listing for Some of its Subsidiaries 3Chrome Group to Seek Listing for Some of its Subsidiaries 4
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home Button ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first time ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming ... than at international borders. Over the past decade, ePassports, ... travelers to self process through border control via eGates ... number of airports, seaports, and land borders across the ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... DALLAS Nov. 16, 2009 As the number of ... "swine flu," continues to rise, researchers have been scrambling to ... lower than expected in older adults. In ... Proceedings of the National Academy of Sciences , a ...
... With 900,000 assisted reproduction treatments annually such as ... to screen both partners before each treatment could lead ... figures do not include the additional overhead costs such ... have to carry on top of that. The new ...
... been awarded nearly $3 million in federal stimulus funds ... Lindsay and Paul Westerhoff will lead a pair of ... fields of rapid DNA sequencing and the potential health ... & Reinvestment Act of 2009 ("Recovery Act" or "ARRA"), ...
Cached Biology News:UT Southwestern scientist begins to unravel what makes pandemic H1N1 tick 2UT Southwestern scientist begins to unravel what makes pandemic H1N1 tick 3Statement of ESHRE on the European Commission proposal of viral screening 2ASU research efforts to improve human health will get $3 million in federal stimulus grants 2ASU research efforts to improve human health will get $3 million in federal stimulus grants 3
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation of endotoxins for research purposes. sensitivity 0.05-0.1 EU/mL...
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
... Ideal for biocompatibility testing at ... circulation of air through a clean ... internal temperature up to 140F. Transparent ... strip shields allow easy access to ...
... Note: Protein determined by Biuret. ... M (NH 4 ) 2 ... Preparation Note: Affinity purified • ... • Additives: MgCl 2 1 ...
Biology Products: